Hereditary hemochromatosis results from inherited disruptions in molecular pathways that regulate iron homeostasis, leading to inappropriately increased absorption of dietary iron through the gastrointestinal tract and subsequent deposition of iron in parenchymal tissues of the liver, pancreas, heart, joints, and other organs. The condition is genetically heterogeneous, with different subtypes involving distinct molecular mechanisms.

The most extensively characterized subtype follows an autosomal recessive pattern of inheritance, in which a person must inherit an altered copy of the relevant gene from each parent to develop the condition. Clinical penetrance in this form is notably low; environmental factors including alcohol consumption, dietary iron intake, and comorbid liver conditions can influence whether and to what degree clinical manifestations develop. Other subtypes of hereditary hemochromatosis exhibit different modes of inheritance, including autosomal dominant patterns, reflecting the genetic diversity of the condition. In rare instances, concurrent variants in more than one iron-metabolism gene can result in iron overload, as seen in digenic hemochromatosis.

Diagnosis of hereditary hemochromatosis draws on laboratory findings, clinical features, and family history. Laboratory evidence of iron overload includes elevated transferrin saturation—with thresholds in the most prevalent subtype of 60% or more in males and 50% or more in females on repeated measurement—and elevated serum ferritin concentration, which may range from mildly elevated values to levels substantially exceeding 1,000 micrograms per liter. Higher mean corpuscular hemoglobin, mean corpuscular volume, and hemoglobin values have been associated with the most prevalent subtype and may indicate the diagnosis when accompanied by elevated transferrin saturation.

Evaluation following a suspected diagnosis may include assessment of liver function with serum transaminase and other hepatic tests, and radiographic assessment of affected joints in those with arthralgia. Liver biopsy may be considered when cirrhosis is clinically evident or serum ferritin is markedly elevated, to characterize hepatic injury and inform prognosis. Noninvasive quantitative MRI can assess iron burden in the liver and other organs when biopsy is not feasible and can also measure iron in the spleen, pancreas, heart, and brain. Genetic testing enables identification of the specific molecular subtype and informs risk assessment for biological relatives.

Therapeutic phlebotomy—the regular removal of a unit of blood—is the established standard of care for hereditary hemochromatosis in individuals with biochemical evidence of iron overload or clinical manifestations of organ damage. It is characterized as a straightforward, safe, and effective means of reducing excess iron stores. Treatment is sustained until iron stores are reduced to target levels, as determined by serum ferritin and related iron parameters. In individuals diagnosed and treated before the development of cirrhosis, iron depletion may prevent progression of organ damage and allow partial recovery of affected tissues.

Erythrocytapheresis, which selectively removes red blood cells while returning plasma and other blood components, represents an alternative iron reduction approach that has been incorporated into recent hemochromatosis management guidelines.

Clinical management guidelines describe ongoing evaluation of organ systems at risk for iron-related injury, including the liver, joints, endocrine glands, and heart, with assessment protocols informed by the individual’s clinical status and iron burden.

The prognosis of hereditary hemochromatosis is closely linked to the presence and extent of organ damage at the time of diagnosis and the effectiveness of iron depletion. For individuals identified and treated before the development of cirrhosis, life expectancy has been described as normal. Those diagnosed after cirrhosis has developed face a reduced life expectancy even with iron depletion therapy, driven primarily by the estimated 10% to 30% risk of primary liver cancer—including hepatocellular carcinoma—associated with established cirrhosis. Failure to achieve adequate iron depletion over an extended treatment period is considered a poor prognostic indicator. Comorbid conditions including alcohol use disorder, viral hepatitis, and nonalcoholic fatty liver disease are recognized contributors to accelerated liver injury and less favorable outcomes. Because clinical penetrance is low across the condition, many individuals with the genetic predisposition remain without clinical manifestations, and prognosis varies considerably across the spectrum of subtypes and disease stages.

Research interest in hereditary hemochromatosis has generated a substantial body of published work, including numerous review articles and publications related to ongoing trials, reflecting sustained scientific activity. Certified active trial records are present for this condition, encompassing studies of investigational pharmacological approaches to iron regulation as well as evaluations of treatment monitoring strategies. Active clinical trials for this condition are listed on ClinicalTrials.gov.